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Insight into the expanding themes of regenerative medicine is provided by the American Society
for Neural Therapy and Repair’s annual meeting. The 17th meeting covered a wide range of
neurodegenerative disorders, exploring methods to elucidate the currently unknown mechanisms
behind the disorders, as well as possible treatments ranging from the use of growth factors, gene
therapy to cell transplantation. The importance of growth factors, both as a contributing factor
to a disease and as a possible treatment either solo, or as a consequence of, or in conjunction
with, stem cell therapy, was highlighted. The potential for viral vectors was also explored either for
cells prior to transplantation or as a direct treatment regime into the brain itself. Identiﬁcation of
biomarkers that would allow early detection of a disease is an important factor in our ﬁght against
disease. The ability to now perform whole genome analysis and biomolecular proﬁling provides
hope that such markers could be identiﬁed which not only could identify this likely to suffer from
a disorder but also could allow its progress to be monitored. A few preclinical and clinical cell
transplantation trials were also introduced as potential areas of followup in the years to come.
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1. INTRODUCTION
The ﬁeld of regenerative medicine is rapidly expanding with new information on the causes of diseases and
possible treatments occurring all the time. This is reﬂected in the diversity of the presentations that occur
annually at the American Society for Neural Therapy and Repair (ASNTR). Many of the presentations are
subsequently expanded on at future meetings or in high proﬁle publications. We therefore feel that a review
of the topics presented at the 17th ASNTR meeting held in Clearwater, Fla, 2010, can provide insight into
the everchanging and evolving ﬁeld of regenerative medicine for neurological disorders.
As shown in Table 1, there is a wide diversity of topics presented at the annual meeting, which can be
split into two camps; speciﬁc disease-related studies and general research on mechanisms, treatments, and
their characterization. Related publications in the TheScientiﬁcWorldJournal over the last two years will be
used to help demonstrate their relevance and provide some perspectives for the readers of this journal.
2. PARKINSON’S DISEASE
As in previous years [1, 2], the most popular disease topic was Parkinson’s disease (PD; Table 1), which
made up approximately 30% of the presentations. These can be further subdivided into studies that explore
the characteristics of the disease in both humans and disease models and those that look at different
treatments ranging from the currently in use deep brain stimulation to new potential therapies such as stem
cell transplantation. Several of the other disease-related topics can be divided in a similar fashion.
Several presentations looked at different models for PD and how they are compared to Parkinson’s
disease. For instance, the rotenone model [3] demonstrates many similarities to PD, and there is some
epidemiological evidence that rotenone is a risk factor for PD. Green et al. [4] compared numerous
models (including the rotenone model reported on by Greenamyre et al. [3]) and demonstrated that similar
gastrointestinal pathology such as alpha-synuclein accumulation is seen in PD and a variety of animal
models. Carvey et al. [5] reported on the dysfunction of the blood-brain barrier (BBB) that has been
observed in several animal models and in PD. Treatment with an inhibitor of angiogenesis has been shown
to reduce BBB impairment, loss of tyrosine hydroxylase (TH) positive neurons, and inﬂammation in a 1-
methyl-4-phenyl 1,2,3,6-tetrahydropyridine-(MPTP) treated mouse model of PD [6]. Different models of
PD have also been explored in TheScientiﬁcWorldJournal, such as the use of organotypic slice cultures of
ventral mesencephalon with unilateral tissue surface application via microelectrode of 6-hydroxydopamine
(6-OHDA) by Stahl et al. [7]. They observed localized and speciﬁc cell death that resembled the effects of
6-OHDA observed in vivo, thus providing another potential model system for exploring PD.
Two studies examined the effects of inﬂammation on the survival of dopaminergic neurons that
are normally lost in PD. Monahan et al. [8] demonstrated that prenatal exposure to lipopolysaccharide
caused increased microglial activation and reduced dopaminergic cell survival, whereas Boger et al. [9]
demonstrated a similar effect on dopaminergic neurons in adult rats. Both authors suggested and Monahan
et al. provided evidence that these effects may result from increased proinﬂammatory cytokine release.
Interestingly, Pab´ on et al. [10] showed data suggesting that the chemokine fractalkine, which is involved
in neuronal-microglial signaling, could be neuroprotective in the 6-OHDA-treated rat due to its ability to
reduce microglial activation. Further studies also explored how alpha-synuclein, the accumulation of which
in the brain is a pathological hallmark of PD, can mediate oxidative stress and microglial activation [11]
whereas another study looked at how dopamine itself could be toxic to dopaminergic neurons [12]. The
possible protective role of uncoupling proteins and mitochondrial homeostasis in young primates that is
observed after MPTP treatment was investigated in another study [13].
In the human alpha-synuclein-overexpressing rat model, silencing of the overexpressing gene was
found to partially rescue forelimb use, but also reduced TH expression, suggesting that silencing of the
overexpressing gene does not mean that the animal reverts back to a wild-type state [14]. Gene transduction
can also be used as a neuroprotectant since overexpression of the growth factor pleiotrophin was found to
promote survival in the 6-OHDA-treated rat model of Parkinson’s disease [15].
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TABLE 1: Distribution of major topics at the 2010 ASNTR meeting.
Number of references
Parkinson’s disease 33
Brain ischemia 15
Alzheimer’s disease 14
Spinal cord injury 8
Transplantation and migration 7
Stem cell characteristics 6
Disease biomarkers and genome
analysis
5
Animal models of disease 4
Huntington’s disease 4
Pain 3
Amyotrophic lateral sclerosis 2
Traumatic brain injury 2
Other 8
Growth factors are known to play an important role in the development and survival of cells. An
increased number of striatal neurons expressing the epidermal growth factor superfamily protein fetal-
antigen-1, which is believed to be a growth and/or differentiation factor, was observed following 6-
OHDA treatment in rats, suggesting that this protein may play a role in PD [16]. Str¨ omberg et al. [17]
demonstrated that glial-derived neurotrophic factor (GDNF) was crucial for the maintenance but not
the original development of the dopaminergic nigrostriatal system. This was achieved by transplantation
of a lateral ganglionic eminence (LGE) and ventral mesencephalon (VM) graft into a host animal and
demonstrating “normal” development with GDNF-deﬁcient tissue. However, this graft did not survive for
six months, whereas GDNF-expressing tissue did. Blanchard et al. [18] used a similar transplant, except
in some cases the orientation of the LGE was reversed, to attempt to demonstrate the existence of a
developmental gradient of growth factors within the striatum. Andressoo et al. [19] presented further data
on how GDNF (or the lack of it) affects the development of the dopaminergic system, whereas Saarma
et al. [20] discussed how cerebral dopamine neurotrophic factor (CDNF) may have a potential role in the
treatment of PD and suggested that it may be a better factor than GDNF in this regard due to its ready ability
to diffuse through brain tissue.
Two studies looked at oral administration of possible neuroprotective agents and found some degree
of success with allantoin, the end product of purine metabolism, in the 6-OHDA-treated rat model [21], and
a peroxisome proliferator activated receptor-γ (PPAR-γ) agonist in the MPTP-treated mouse model [22].
The possible involvement of this receptor as a therapeutic target was reviewed in an article published in
TheScientiﬁcWorldJournal [23]. Of particular interest are the receptor’s anti-inﬂammatory, proapoptotic,
and cell cycle arresting properties and how they could interact with disease processes. Subcutaneous
administration of a full dopamine D1 receptor agonist was also shown to exert behavioral beneﬁts in the
6-OHDA-treated rat [24]. These studies are the roots for further evaluation of these compounds as potential
treatments for PD.
Dodiya et al. [25] looked at human postmortem tissue and provided evidence that striatal dopamine
innervation by nigral neurons dropped off rapidly in patients with more than 5 years disease duration,
which may mean that trophic factor therapies that rely on retrograde transport mechanisms are likely to be
ineffective due to the absence of surviving dopaminergic projections. PD patients that had only recently
been diagnosed who are also on antidepressants have been shown to be less behaviorally impaired than
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those who are not, suggesting that antidepressant therapy might provide some beneﬁt[ 26]. Data from
two clinical studies were presented that explore the potential of deep brain stimulation (DBS) in early
PD patients [27, 28]. A third study of deep brain stimulation in PD touched on the possible beneﬁcial
effects of this treatment on speech problems and whether an algorithm could be created which could
monitor this as previously reported results are mixed [29]. By comparison, a few studies published in
TheScientiﬁcWorldJournal looked at whether complementary treatments such as active theater or mental
and physical exercise could be beneﬁcial in PD, cognitive impairment, and aging [30–32]. Modugno et al.
[30] observed a signiﬁcant improvement in the clinical scale of PD patients after 3 years of an active theater
program compared with patients on physiotherapy. Frick and Benoit [31] reviewed animal models that
used environmental enrichment, focusing primarily on the effects on aging, where cognitive improvement
(or stabilization) has been seen, while Asha Devi [32] focused on the ability of exercise and a vitamin E
regimen to slow cognitive decline.
One possible treatment for PD that has previously been explored is transplantation. Early studies
focused on tissues and two studies presented at the ASNTR meeting also elaborated on this type of
treatment. Rao et al. [33] showed that cografts of human retinal pigment epithelial cells and striatal mouse
VM in 6-OHDA-treated rats survived better than VM alone and also produced behavioral improvements.
Soderstrom et al. [34] reported that graft survival and dyskinesia incidence improved when embryonic
dopaminergic tissue that had been pretreated with calcium channel inhibitors to promote medium spiny neu-
ron dendritic spine survival was grafted, suggesting that spines are important in the derivation of grafts and
in reducing side effects. Surmeier [35] reviewed the possible contribution of calcium channels in dopamin-
ergic neurons to the generation of oxidative stress and the selective vulnerability of these cells in PD.
As well as transplanting tissue, studies are progressing towards the transplantation of speciﬁc cell
types, such as stem cells. Three studies looked at the potential beneﬁts of transplanting human-derived
neural progenitor cells into the 6-OHDA-treated rat [36, 37] or MPTP-lesioned primate [38]. The cells
used by Collier et al. [36] included cells from NeuralStem, Inc. Endogenous neurogenesis was shown to be
promoted by Madhavanet al. [37], whereas growth factors were also shown to play a role in cell survival and
demonstrated some beneﬁt in each study. Wakeman et al. [38] actually pretreated the animals with adeno-
associated virus-GDNF to explore the effects of this factor on transplantation. Interestingly, Kelly et al. [39]
used a similar approach to “enrich the environment” prior to human umbilical cord blood transplantation in
MPTP-treated primates, and neuroprotective effects were observed in all of these studies. The ﬁnal reported
cell transplantation study for PD used human mesenchymal stem cells (hMSCs) transplanted into the 6-
OHDA-treated rat and again showed that growth factors played a role in the cells’ survival and beneﬁts [40].
These studies are summarized in Table 2 and show that PD research is progressing with research
expanding our understanding of what goes wrong in Parkinson’s disease and how current treatments, such
as deep brain stimulation, may prove to be beneﬁcial in the early stages of the disease. Potential treatments
are likely to focus on ways to promote growth factor expression which can provide an environment more
favorable to cell survival and promote endogenous neuronal survival, possibly by stem cell transplantation
or other means.
3. BRAIN ISCHEMIA
The second largest disease-related category is that of brain ischemia; the majority of the studies focused
on stroke. Since tissue-plasminogen activator (t-PA) is currently the only FDA-approved treatment for
stroke and this has a small window of effectiveness, it is imperative that other therapies can be identiﬁed.
This group highlights this, since in contrast to the PD group, these studies exclusively explored possible
treatment regimes including the use of diet, growth factors, or cell transplantation. Borlongan et al. [41]
demonstrated that proprietary herbal extracts of cacao and red sage could confer neuroprotection in both
the in vitro oxygen-glucose deprivation (OGD) primary neuronal culture and in vivo middle cerebral artery
occlusionrodentmodels(MCAo)ofstroke.Interestingly,theextractswereonlyeffectiveinvivowhengiven
prophylactically. Three studies looked at using adeno-associated viral vectors (AAVs) for trophic factors
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TABLE 2: Summary of Parkinson’s disease studies at the 2010 ASNTR meeting.
Disease pathology Models Neuroprotection Transplant Treatments
Morphological
Etc
BBB
impairment [5, 6]
Rapid loss of
striatal DA
innervations
[25]
calcium [35]
Rotenone
[3, 4]
Uncoupling proteins
[13]
Cografts [33],
tissue + calcium
channel
inhibitors [34],
NPCs [36, 37],
hMSCs [40]
DA receptor
agonist [24],
antidepressants
[26],
DBS [27–29]
Gene therapy
α-Synuclein
silencing [14],
pleiotrophin [15]
GDNF + NPCs
[38],
GDNF + hUCB
[39]
Inﬂammation
Increased [8, 9, 11]
DA toxicity [12]
Reduced microglial
activation [10]
Allantoin [21]
PPAR-
γ [22]
Growth factors
Fetal-antigen 1
overexpression in
striatum [16]
GDNF and
development [19]
CDNF [20]
GDNF + tissue
grafts [17, 18]
such as mesencephalic astrocyte-derived neurotrophic factor (MANF) and vascular endothelial growth
factor (VEGF), or the glutamate transporter (GLT1) in an MCAo (or focal cerebral ischemia) rat model of
stroke or ischemia [42–44]. In each case, a reduced infarct size was observed, with the mechanism of action
being proposed as modulation of endoplasmic reticulum stress, activation of Akt, and reduced extracellular
glutamate, respectively. Interestingly, the combined use of stem cell factor (SCF) and granulocyte-colony
stimulating factor (G-CSF) was shown to promote neuronal network formation after cortical ischemia [45],
as well as promote blood ﬂow, and reduce cerebral amyloid angiopathy in an animal model of inherited
stroke and vascular dementia called cerebral autosomal dominant arteriopathy with subcortical infarcts and
leukoencephalopathy (CADASIL) [46]. These studies provide support for the use of combination therapies
to treat disorders.
Pretreatment with pyruvate was also shown to confer some protection in an OGD hippocampal slice
model, which may relate to the ability of pyruvate to increase glycogen stores [47]. OGD and the MCAo
rat model were used to investigate the ability of human umbilical cord blood cells (hUCBCs) to modify
the neuronal gene expression proﬁle both in vitro and in vivo following ischemia and saw changes in
transcription factors that could promote neuronal survival [48].
Bible et al. [49] characterized a 19F-contrast agent for the labeling of different human neural stem
cell (NSC) lines so that they could be followed after transplanting them into stroke-lesioned animal
brains. On the other hand, Daadi et al. [50] used superparamagnetic iron oxide particles (SPIOs) to label
human embryonic-stem-cell-(ESC) derived NSCs that could be monitored by magnetic resonance imaging
following transplantation into the MCAo-treated rodent brain. They observed a marked reduction in the size
of the infarct over time and monitored the survival and location of the transplanted cells.
Two studies investigated ReNeuron’s immortalized neural stem cell line that is currently undergoing
clinical trials for the treatment of stroke in the United Kingdom. The ﬁrst study looked at i.v. administration
of the cells within 2 days of MCAo in rats [51], whereas the second study transplanted cells either directly
into surviving brain tissue or into the ventricles 3 weeks after MCAo [52]. The acute treatment showed
signiﬁcant improvement in the elevated body swing test within 3 days. A similar recovery in this and
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TABLE 3: Summary of the ischemia studies at the 2010 ASNTR meeting.
Models Neuroprotection Transplant Treatments
Morphological
Etc
Cell labeling [49, 50]
ReNeuron’s
immortalized NSC
[51, 52]
Diet [41]
Pyruvate [47]
Gene therapy
MANF [42], VEGF
[43],
GLT1 [44]
Growth factors
Upregulation of HSP27
after embryonic-like
stem cell coculture [60]
SCF and G-CSF
[45, 46]
NSCs + VEGF
scaffold [53]
Autologous peripheral
blood SCs + G-CSF
[59]
other behavioral tests was observed over a 3-month period following parenchymal but not ventricular
transplantation.
One study combined the use of stem cells and growth factors by transplanting human NSCs
within a VEGF-releasing microparticle scaffold into the stroke-induced lesion of rats [43, 53]. They
observed some indication of increased vascularization within the lesion. Several papers published in
TheScientiﬁcWorldJournal [54–58] looked at the potential beneﬁts of the angiogenic protein, erythropoietin
for the treatment of stroke. These studies included those demonstrating beneﬁt when erythropoietin was
administered intranasally or by other routes [54, 55, 58], and Hermann [56] explored possible variants of
the molecule that maintain the neuroprotective but not the hematopoietic actions of the molecule. While this
compound was not explored at this meeting, it was a topic of interest at previous meetings and could tie in
with the proangiogenic properties of VEGF (e.g., [43, 53]).
One clinical study using intracerebral transplantation of autologous peripheral blood stem cells in old
stroke patients was also reported [59]. They observed behavioral improvements only when the cells were
combined with G-CSF, which can aid the mobilization of the transplanted cells.
Using dog placenta as a source of embryonic-like stem cells, Yu et al. [60] demonstrated increased
cell survival of primary rat neurons/astrocytes that were cocultured with these cells after OGD treatment.
Theauthorsdemonstratedthatthebeneﬁcialeffectmayresultfromanupregulationofheatshockprotein27.
These studies are summarized in Table 3 and show that there are several potential cell transplantation
procedures currently being studied that could confer some degree of recovery from a stroke. A number of
different cell types have so far been explored, and the optimal type and route of delivery awaits identiﬁca-
tion. Alternative remedies such as growth factors are also being tested to modify the microenvironment and
possibly promote neurogenesis, although combined studies may prove to be the most effective.
4. ALZHEIMER’S DISEASE, AGING, AND COGNITION
Alzheimer’s disease (AD) is the most common neurodegenerative disease observed in man, and it is always
a popular topic at the ASNTR meeting. In this group, we are also including aging and cognitive impairment
as they can relate to AD. As with PD, this section includes articles on furthering our understanding of the
disease, as well as possible treatments such as diet or natural supplements, neurotrophic factors, or cell
transplantation for improving cognition or treating the disease.
Mervis et al. [61] studied how cortical neuroplasticity and neurodegeneration change from the
suspected precursor to AD, mild cognitive impairment (MCI), to full blown AD. They observed frontal
cortical increases compared with parietal and temporal decreases in synaptic plasticity in MCI, whereas
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all regions were decreased in AD. Spine density was also found to be reduced in both MCI and AD
patients.
The use of dietary or natural supplements included epigallocatechin-3-gallate (EGCG), an extract
from green tea. This has previously shown promising preclinical results but has limited potential due
to the molecule’s poor bioavailability. Using a nanoparticle assembly to stabilize EGCG was shown to
potentiate its beneﬁcial effects in vitro and its bioavailability in vivo [62]. In addition, the supplement
NT-020, derived from blueberries and other natural products, was shown to promote spatial memory,
increase neurogenesis, and decrease inﬂammation in aged rats, suggesting it could have beneﬁcial effects in
treating the cognition-related effects of aging and possible AD [63]. Freeman and Granholm [64] continued
their investigations of the effects of a high-fat/high-cholesterol diet and showed that prolonged treatment
compromised the BBB and promoted inﬂammation and hippocampal damage. Dietary effects on AD
were also explored in TheScientiﬁcWorldJournal where two reports looked at dietary fatty acids [65, 66].
Interestingly, Mohagheghi et al. [67] reported in TheScientiﬁcWorldJournal that intake of virgin olive oil
appeared to reduce the BBB permeability and other effects observed in rats subjected to ischemia, providing
further evidence of dietary impacts on disease and the involvement of the BBB.
There are two major pathological hallmarks of AD, the presence of amyloid plaques, due to the accu-
mulation of β-amyloid (Aβ)and neuroﬁbrillary tangles, due to excess tau phosphorylation and aggregation.
SomeofthestudiesofthediseasemodelattheASNTRmeetingfocusedononeortheotherofthesepatholo-
gies. Borysov et al. [68] report that Aβ inhibits the microtubule-based motors that are crucial for the organi-
zation and function of the microtubule cytoskeleton, which could lead to aneuploidy and impaired synaptic
activity. Conversely two studies focused on tauopathies exploring the importance of heat shock protein 27
and inﬂammation in the generation of hyperphosphorylation and aggregation of tau [69, 70] .Ar e v i e wo f
heat shock proteins was also recently published in TheScientiﬁcWorldJournal [71] which explored how they
may act to promote the removal of damaged or misfolded proteins (such as hyperphosphorylated tau).
Zhu et al. [72] demonstrated what they believe is an improved AD model; presenilin-amyloid
precursor protein (PSAPP) mice which do not express CD45. These mice were found to exhibit
greater neurodegeneration as well as higher levels of intra- and extracellular Aβ, but decreased plasma
Aβ compared with PSAPP mice expressing CD45.
Brownlow et al. [73] used an AAV to overexpress neprilysin, an enzyme that breaks down amyloid,
in the PSAPP mouse and showed that amyloid deposits were reduced. By comparison, Li et al. [74] showed
that amyloid deposition in the PSAPP mouse could also be reduced by treating with the neurotrophic factors
SCF and G-CSF. The authors also observed an increased presence of microglia around plaques, and they
proposed that these factors may promote the targeting of microglia to the plaques which can then clear
them. The interaction between microglia and neurons was also explored further by studies looking at the
protein fractalkine which is found on neurons and its receptor CX3CR1 which is found on microglia. The
absence of the receptor in knockout (KO) mice was shown to reduce hippocampal synaptic plasticity and
neurogenesis [75], whereas the different roles of the soluble and membrane-bound forms of fractalkine were
explored using AAV vectors [76]. The potential role of microglia and inﬂammation in aging and AD has
been previously reported in TheScientiﬁcWorldJournal [77–79]. For instance, Solomon [79]r e v i e w e dt h e
current state of immunotherapies such as Aβ antibodies for the treatment of AD discussing their success in
animal models and the problems with translating to the clinic, while Brown [78] presented an overview of
how subtle age-related changes in microglia could lead to a gradual neuronal loss.
Cognitive impairment has also been observed with sufferers of gulf war illness. A rat model of this
disorder, that involves exposing the animals to a cocktail of chemicals similar to those the veterans may
have been exposed to, showed an impairment in learning and memory that is related to a prolonged decline
in hippocampal neurogenesis [80]. This could be a possible cause of at least some of the neurological
symptoms observed.
Unfortunately, cognitive deﬁcits are also frequently a side effect of irradiation therapy for the
treatment of brain tumors. Acharya et al. [81] transplanted human embryonic stem cells into rats after
head only irradiation and found that the transplanted cells that survived had differentiated into neurons,
1848TheScientiﬁcWorldJOURNAL (2011) 11, 1842–1864
TABLE 4: Summary of the Alzheimer’s disease, aging, and cognition studies at the 2010 ASNTR meeting.
Disease pathology Models Neuroprotection Transplant Treatments
Morphological
Etc
Cortical plasticity [61]
Aβ and microtubules [68]
PSAPP CD45
[72]
Gulf war
illness [80]
Dietary
supplement [63]
hESCs for
radiation-induced
cognitive
impairment [81]
Neonatal transplant
of NPCs into DS
mouse [82]
Diet [62]
Gene therapy
Neprilysin [73]
Fractalkine KO [75]
Fractalkine
soluble/membrane [76]
Inﬂammation
High-fat/high-cholesterol
diet [64]
Tauopathies [69, 70]
Growth factors SCF and G-CSF [74]
astrocytes, and oligodendrocytes and improved the cognitive deﬁcits that are frequently seen. The authors
did not report whether the cells had resulted in tumors, but further studies could show that this may be a
potentially interesting treatment for some of the side effects of irradiation therapy.
Cognitive impairment is also a major characteristic of Down’s syndrome which is caused by the
trisomy of chromosome 21 (including the APP gene). Rachubinski et al. [82] investigated whether neonatal
transplantation of mouse NPCs into a transgenic mouse model of Down’s syndrome resulted in cognitive
improvements in adulthood. Unfortunately, they observed no signiﬁcant beneﬁcial effects with the tests that
they used.
These studies are summarized in Table 4 and show that there are a number of ways that are effective
in animal models that can be applied to remove amyloid deposition and try and improve Alzheimer’s
disease. However, Bartfai [83] presented an article in TheScientiﬁcWorldJournal which discusses how the
majority of studies are focused on removing amyloid deposition and how these studies in animals have not
translated well to the human condition. This goes hand in hand with the fact that our understanding of the
disease is still unfolding, and it would appear that this route (i.e., removal of amyloid deposition) may not
be sufﬁcient by itself to treat AD. Further studies are required to determine if these treatments will also
affect the tauopathy observed in AD. Some of the data above suggests that progress is being made in our
understanding of how we can alter the underlying causes of the pathology, though in all likelihood there
is still some way to go before a suitable therapy reaches the clinic. Combined therapies that also target
neurogenesis and inﬂammation are likely to prove to be more beneﬁcial than those that focus exclusively
on removal of amyloid deposition. Dietary manipulation and improved animal models of the disease as
presented at the meeting are two possible avenues that may prove fruitful in the years to come as our
understanding of the disorder progresses.
5. SPINAL CORD INJURY, PAIN, AND AMYOTROPHIC LATERAL SCLEROSIS
Spinal cord injury (SCI) is a frequent side effect of car accidents and other injuries to the back, which
frequently target the young and can result in many years of disability. There are no real therapies that
effectively cure the injury, but research is ongoing to ﬁnd potential treatments. A review of the current
research for SCI performed in mice was recently published in TheScientiﬁcWorldJournal [132]i nw h i c h
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the authors discussed a variety of approaches including genetic and molecular engineering and how they
could lead to advances in potential methods for repair and regeneration of the injured spinal cord.
For instance, three studies from the same researchers presented at the ASNTR meeting further
explored how the location of the injury, that is, white matter versus combined white and grey matter injury,
can dictate the degree of neuroplasticity with respect to the respiratory drive that is observed. Lane et
al. [84] showed compensatory improvements following a white matter injury, while Mercier et al. [85]
demonstrated compensatory contralateral phrenic motor activity following a similar injury. In contrast,
Salazar[86]presenteddataoncombinedgreyandwhitematterSCIwhichdidnotinducesigniﬁcantchanges
in ventilatory function.
Hentall et al. [92] reported that early electrical stimulation of the raphe nucleus after an SCI speeds
up recovery, and they propose that this is likely to result from the action of 5-hydroxytryptamine (5-HT) or
other peptides released from the axon terminals in the spinal cord.
One of the biggest problems with spinal cord injury is the formation of a glial scar zone which is
not conducive for repair. Therefore, one possible treatment is to provide a scaffold that can offer a more
favorable repair environment. Khaing et al. [87] reported on using hyaluronan and laminin hydrogels as
scaffolds that can prevent or modify the scar tissue to promote recovery. This scaffold could also be used to
support a cell transplant. For instance, Sykova et al. [88] reported on using a hydrogel seeded with MSCs
to treat acute and chronic SCI. They found that the transplant would reduce the size of the scar and tissue
atrophy (if given acutely), help bridge the lesion, and increase functional activity (though not without the
stem cells). This scaffold for regeneration was shown to integrate into the cavity and also be inﬁltrated by
blood vessels and axons.
Busch et al. [96] transplanted rat multipotent adult progenitor cells at the time of injury and found
that these cells reduced axonal dieback and promoted neurite outgrowth in a rat model of SCI and this may
result from factors secreted by the cells. By comparison, Yu et al. [89] transplanted human neural stem cells
within 3 days of SCI and observed restoration of respiratory function, as well as showing evidence of tissue
reconstitution and neurite reorganization.
Oneofthesymptomsofspinalcordinjurycanbeseverepain,andthereiscurrentlyanFDA-approved
drug available which is a synthetic version of a conotoxin. One study demonstrated that gene therapy
could be used to consistently transduce expression of conopeptides within the spinal cord [93]. However,
no information on their antinociceptive activity was provided. Lee et al. [94] using a similar adenovirus-
conotoxin construct, which they injected into the left sciatic nerve of rats and mice, demonstrated a reduced
responsetoformalininjection,suggestingthatconotoxingenetherapycouldbeusefulfortreatingperipheral
neuropathic pain.
Jergova et al. [90] assessed whether transplantation of a gamma aminobutyric acid (GABA)ergic
neural progenitor cell could help alleviate peripheral neuropathic pain in a rodent model. They observed
decreasedhyperalgesia and allodynia and demonstrated that the antinociceptive effect was GABA mediated.
A recent report in TheScientiﬁcWorldJournal [133] focuses on the recently announced termination of
many studies by a number of major pharmaceutical companies as they streamline their research. One of the
avenues of research that was apparently dropped is the development of drugs for neuropathic pain, which is
unfortunately considering the studies mentioned above and their potential promise.
Amyotrophic lateral sclerosis (ALS) results from the progressive loss of spinal motor neurons by an
as yet unknown mechanism. Two studies reported on cell transplants for this disorder. Human umbilical
cord blood cells were administered intravenously into the G93A ALS mouse model and were observed to
delay disease onset and increase lifespan. Immunohistochemical analysis revealed a reduced presence of
activated microglia supporting an anti-inﬂammatory beneﬁt for these cells [95]. The second study reported
on the start of a Phase I clinical trial using NeuralStem Inc.’s human fetal spinal cord-derived NSCs for
the treatment of this disease [91]. This trial will include immunosuppression and initially involve lumbar
transplants, which once proven safe will progress to cervical transplants. The animal studies this trial is
based on showed that these cells were capable of forming synaptic connections and secreting a number of
neurotrophic factors that could facilitate recovery.
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TABLE 5: Summary of the spinal cord injury, pain, and ALS studies at the 2010 ASNTR meeting.
Disease pathology Models Transplant Treatments
Morphological
Etc
White matter versus
grey matter [84–86]
Scaffold [87]
Scaffold
+MSCs [88]
NSCs [89]
GABAergic
NPCs for pain
[90]
Neural stem
for ALS [91]
Electrical
stimulation [92]
Gene therapy
Conotoxin for
pain [93, 94]
Inﬂammation
hUCB for
ALS [95]
Growth factors MAPCs [96]
There is some promising research for the treatment of SCIs and pain that could prove to be effective,
and the studies from the ASNTR meeting are summarized in Table 5. Combined treatments such as scaffold
and cells may turn out to be the most effective as they have potential in promoting the restoration of
connectivity across the glial scar.
6. HUNTINGTON’S DISEASE
Huntington’s disease (HD) is an autosomal dominantly inherited progressive neurodegenerative disorder
that involves severe brain atrophy and deﬁcits in motor ability and cognition. The cause of the disease
is multiple glutamine repeats in the huntingtin protein, and there are several animal models available. At
the ASNTR meeting, one study provided a detailed analysis of the CAG140 knockin mouse model, that
has 140 glutamine repeats [99]. They observed an increasing incidence of neuronal intranuclear inclusions
over time as well as a progressive decrease in cortical thickness. A second presentation studied the R6/2
transgenic mouse model of HD, which expresses exon 1 of the human mutant huntingtin gene, providing a
detailed analysis of the functional and neuropathological changes that occur over time [100]. Motor deﬁcits
developed between 4 and 8 weeks of age, and magnetic resonance imaging (MRI) analysis was used to
correlate any changes in regional brain volume.
Two additional studies using the R6/2 mouse model involved cell transplantation as a possible
treatment. El-Akabawy et al. [103] transplanted human striatal NSCs directly into the striatum and found
no improvement of motor deﬁcits, but did observe an improvement in the swimming T-maze. This
suggests that with some reﬁnement of the technique, this treatment may prove to be useful in treating
HD. By comparison, Rossignol et al. [104] transplanted low-and-high passage MSCs into the striatum and
observed greater behavioral improvement with the lower passage than the higher passage cells supporting
the idea that “younger” cells may be better. A possible mode of action may be their ability to secrete
growth factors such as brain-derived growth factor (BDNF). Tebano et al. [134] published a manuscript
in TheScientiﬁcWorldJournal that discussed how adenosine receptors and BDNF levels could contribute to
the pathogenesis of HD since an impairment of both appears to be involved. A normal level of adenosine
receptor activation is required for the maintenance of BDNF levels, and so reduced adenosine signaling will
also lead to reduced BDNF.
These studies are summarized in Table 6 and show that cell transplantation could be beneﬁcial as
a treatment for HD, based on their effects in the R6/2 model of HD. This model exhibits a number of the
characteristics of HD, making it a potentially effective model.
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TABLE 6: Summary of the Huntington’s disease and other disorder studies at the 2010 ASNTR meeting.
Disease pathology Models Transplant Treatments
Morphological
Etc
Epilepsy loss of
reelin+
interneurons [97]
Sanﬁlippo:BBB
impairment [98]
CAG140 knockin
mouse model [99]
R6/2 model [100]
Microlesions [101]
Neurogenesis and
sexual dysfunction
[102]
HD: NSCs [103]
HD: MSCs [104]
TBI: raphe
stimulation [105]
Growth factors TBI [106]
7. OTHER NEUROLOGICAL DISORDERS
Traumatic brain injury (TBI) is a frequent consequence of war time that results in immediate extensive brain
damage and severe neurological impairment. Recent studies suggest that there may also be a secondary
progressive damage which maybe easier to treat. Shojo et al. [106] using the moderate ﬂuid percussion
model of TBI demonstrated a rapid increase in interleukin-1 (IL-1) and tumor necrosis factor (TNF) which
peaked three hrs after injury. Apoptosis was seen to progressively increase from 3hrs onwards to plateau
at 48hrs by which time IL-1 and TNF had returned to normal levels. Using the same model, another group
showed that early intermittent stimulation of the rat dorsal or median raphe for a week restored some of the
cognitive and motor deﬁcits caused by TBI [105].
The symptoms of temporal lobe epilepsy (TLE) consist of spontaneous recurrent motor seizures
(SRMS) and cognitive deﬁcits and can be induced in rats by the use of graded intraperitoneal injections of
kainic acid. Grier et al. [97] demonstrated that there is signiﬁcant loss of reelin+ interneurons that correlates
with impaired learning and memory, but not with SRMS frequency.
Sanﬁlippo type B is a progressive disorder that results in the accumulation of cerebral and systemic
organ abnormalities due to glycosaminoglycan accumulation within cells as a consequence of a deﬁciency
in the catabolic enzyme, alpha-N-acetylglucosaminidase. Impairment of the BBB has been shown in a
number of disorders (see the previously referred to reports by Carvey et al., Freeman and Granholm at
ASNTR [5, 64] and Mohagheghi et al., Thal in TheScientiﬁcWorldJournal [67, 135]. Thal proposes that
altered drainage of extracellular ﬂuid due to impairments in the BBB competes with perivascular drainage
and could result in the accumulation of Aβ and other proteins within the brain). Garbuzova-Davis et al. [98]
established that BBB impairment can also be seen in animal models of Sanﬁlippo type B. This shows that
deﬁciencies in the BBB may have an important part to play in many diseases and disorders, and therefore
ways to repair the BBB could prove to be therapeutic.
Many brain disorders could potentially be treated by increased neurogenesis, but in many cases
this has been reported to be reduced in the disease state. Song et al. [101] demonstrated that stereotaxic
microlesions caused by a microneedle into speciﬁc brain regions could induce new neurons and glia in
the damaged nonneurogenic regions, by the migration of NSCs or even bone-marrow-derived stem cells.
Elucidation of the pathways which trigger neurogenesis in response to microlesions could be valuable in
the development of neurodegenerative disease therapies, and, according to the authors, may also provide
a mode of action for deep brain stimulation. Recent evidence suggests that neurogenesis may also affect
other processes since sexual activity was elevated in male rats that had been treated with a drug that has
been shown to promote new neuron formation [102]. This demonstrates that control of neurogenesis not
only may be useful for the repair of neurodegenerative disorders but also could impact more social disorders
such as sexual dysfunction.
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These studies are summarized in Table 6 and show that there are a number of different models
available for the study of disease which can be used to investigate the effects of transplantation and
treatments such as neuronal stimulation and the role of growth factors is again important.
8. DISEASE BIOMARKERS AND GENOME ANALYSIS
Many neurodegenerative disorders involve the progressive loss of speciﬁc areas of the central nervous
system (CNS). Frequently, by the time symptoms are observed, the damage is substantial, so the search
for biomarkers that could indicate the likelihood to develop a disease is a potentially important weapon in
treating these disorders early while the damage is not too severe. Mhyre et al. [107] reported on a pilot study
toseeifbiomolecularproﬁlingofperipheralleukocytescouldbeusedtodistinguishbetweendifferentforms
of dementia. They observed disease-speciﬁc alterations in gene and protein expression, which on repetition
in larger studies could lead to speciﬁc biomarkers for dementia-related disorders. Lanari and Parnetti [136]
report in TheScientiﬁcWorldJournal on the presence of biomarkers in MCI patients that could allow one
to predict whether they will progress to AD. They observed that baseline CSF levels of Aβ42, total tau
[T-tau], and phosphorylated tau [P-tau] were altered in MCI patients who progressed to exhibit dementia
over a three-year period. An additional paper by Farnaud et al. [137] reviewed whether saliva could be an
effective source of biomarkers for cancers and other disorders.
Different clustering methods of nuclear magnetic resonance (NMR) were shown to be able to
distinguish between R6/2 HD mice of different age groups and wild-type mice with 100% accuracy [108].
The authors believed that this technique could be reﬁned further to be able to distinguish between other
disorders also.
The presidential symposium proposed the question of paleoneurology, the concept that neurode-
generative disorders are evolutionary new as a consequence of the development of the relatively recent
complexity of the brain [112]. The high plasticity of the brain may be a sign of rapid evolution. Hardy
[113] discussed how whole genome analysis has now progressed to the point where genetic risk factors for
numerous diseases are being identiﬁed. The microtubule-associated protein tau has been shown to be a risk
loci for a number of disorders. Its evolutionary history and unusual European loci structure may suggest
that its disease association could relate to changes in the gene expression of different haplotypes.
Lineage mapping of glioblastomas suggested that the cells which comprise a glioma are polyclonal
nonhierarchical neural stem cells in origin [114]. These cells were found to be steered towards inappropriate
gliogenesis rather than a neuronal fate, which was shown to be reversible.
These studies are summarized in Table 7 and show that current advances in genetic analysis and
biomolecular proﬁling are leading to the identiﬁcation of potential biomarkers for disease, which need to
be evaluated further to determine their speciﬁcity.
9. ANIMAL MODELS OF DISEASE
New animal models of disease are being generated by altered expression of speciﬁc genes. For instance,
knockout of the inducible form of nitric oxide synthase (NOS2) results in an animal model that exhibits
excess neuroinﬂammation, which could lead to elucidation of the role of NOS2 in inﬂammatory and
neurodegenerative disorders [115]. The role of inﬂammation in neurodegeneration has been directly
explored at previous ASNTR meetings as well as a number of reports presented herein (e.g., [6, 9, 63,
64, 70, 115, 131]). The topic of inﬂammation has also been heavily featured in TheScientiﬁcWorldJournal
(e.g., [77, 138–141]) with Catania et al. [138] exploring the possible role of melanocortins in inﬂammation.
Claria et al. [140] and Bannenberg [77] discussed the role of lipid mediators, while D´ ıez-Dacal and
P´ erez-Sala [141] expanded on the contribution of cyclopentanone prostaglandins. El-Kebir and Filep [139]
studied ways to terminate inﬂammation, such as the use of cyclin-dependent kinase inhibitors to trigger the
apoptosis of neutrophils and thus remove their contribution to the inﬂammatory response.
Useofaviralvectortoexpressmelanopsin,alight-sensitivephotopigment,inthesurvivingganglions
of mice with deﬁcient photoreceptors (rd/rd) was found to restore some of the visual function [111].
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TABLE 7: Summary of the disease biomarkers and animal model studies at the 2010 ASNTR meeting.
Disease pathology Models Gene therapy
Morphological
Etc
Peripheral leukocyte
markers [107]
Different clustering methods of
NMR [108]
DS model [109]
Model for PD symptom: cardiac
dysautonomia [110]
Melanopsin for visual
impairments [111]
Gene analysis
Paleoneurology [112, 113]
Glioblastomas [114]
Inﬂammation NOS2 KO [115]
A Down’s syndrome mouse model (TS65Dn), which exhibits some of the neuropathological
hallmarks of AD over time, can be used to investigate the development of these features. For instance,
this model develops loss of the basal forebrain cholinergic neurons (BFCNs). This may result from
reduced levels of nerve growth factor (NGF) binding to their receptors and thus decreased survival signals
(retrograde transport of the NGF/receptor complex), leading to cell death [109].
One of the less common symptoms of PD includes nonmotor symptoms including neurodegeneration
of the autonomic nervous system. The resulting dysautonomias have not been well modeled. Joers et al.
[110] proposed using systemic 6-OHDA to induce cardiac dysautonomia in primates to generate a model
that could be used to investigate potential treatments.
New animal models are summarized in Table 7 and can be used to mimic speciﬁc aspects of a disease
such as dysautonomia or excessive inﬂammation to help reveal new treatments for symptoms that result
from the disorder and provide further information on the possible causes of these “side effects” in the larger
picture of the disease or disorder.
10. STEM CELL CHARACTERIZATION AND VIRAL VECTORS
As well as studying speciﬁc diseases, ASNTR also focuses on the development and characterization of
stem cells for future applications as possible treatments. For instance, elucidation of the pathways involved
in the differentiation of stem cells to a speciﬁc phenotype is of utmost importance. El-Akabawy et al. [116]
reported on the use of purmorphamine, a sonic hedgehog signaling molecule to produce more neurons
that are DARPP-32+ (dopamine and cyclic AMP-regulated phosphoprotein 32KDa) from a human striatal
neural cell line in preference to astrocytes. These cells can be potentially useful for the treatment of
HD, since DARPP-32+ neurons are the cell type predominantly lost in HD. Gene delivery by retrovirus
of speciﬁc lineage instruction factors (e.g., dominant-negative Olig2 to suppress glial fate, or Pax6 to
promote the neuronal phenotype) into NSCs was also shown to result in differentiation to speciﬁc neuronal
phenotypes by Klempin et al. [126].
Nash et al. [127] provided the proof of principle that recombinant AAV (rAAV) could be used to
insert transgenes into murine NSCs with serotype 1 being most effective and serotype 5 the least. This was
expanded on by the work of Manfredsson et al. [129] who showed that use of an rAAV type 2 with mutated
tyrosine residues (to reduce ubiquitination and hence clearance of the plasmid from the body) promoted the
transduction of speciﬁc genes into cells within the striatum of rats. Using what Nash et al. [127] reported
was the least effective serotype, Nan et al. [130] successfully transduced green ﬂuorescent protein using
rAAV5 into the brains of mice following either a neonatal or adult ventricular injection that persisted for
at least 4 months. Neonatal delivery was shown to be more effective. These three studies demonstrate the
ability to insert speciﬁc genes into neural cells either in vivo or in culture.
Plasmid transduction can also result in immortalization. Using either a respiratory syncytial virus
or elongation factor 1 promotor, the N-terminal SV40 large T antigen fragment was transfected into rat
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TABLE 8: Summary of the stem cells, characteristics, transplantation, and migration studies at the 2010
ASNTR meeting.
Differentiation Models Cell Sorting Transplant
Morphological
Etc
Purmorphamine [116]
Rostral migratory stream
[117]
Trophogel for
culturing [118]
M R Io fm e t a b o l i c
activity [119]
Cell scoring system
[120]
Gap junction
development [121]
Neonatal transplant of
NSCs into DS model
[122]
Neonatal tolerization
[123]
hUCB for glutaric
aciduria [124]
Nanoparticles enter
inner ear [125]
Gene therapy
Speciﬁc lineage
instruction factors [126]
Transgene insertion
into NSCs [127],
Plasmid
transduction and
immortality [128]
Transgene insertion into
striatum [129, 130]
Inﬂammation Homing signal [131]
primary mesencephalic cultures to induce immortalization [128]. Interestingly, only partial incorporation
of the plasmid was observed, suggesting that immortalization may have been spontaneous, when linearized
plasmids are used.
Solanky et al. [119] reported on the use of magnetic resonance spectroscopy of in vitro cell extracts
to distinguish between the more metabolically active undifferentiated NSCs and differentiated cells. This
could prove to be useful in tracking transplanted cells and following their fate if it can be translated to an in
vivo setting.
Song et al. [118, 120] presented two studies on UCB-derived MSCs. In the ﬁrst, they used trophogel
(a placental-derived matrix) as a substrate for the culturing of the cells and demonstrated that this helped
maintain the adhesion and proliferative capacity of these cells [118]. Their ability to differentiate into
bone and fat cells was also studied and found to be increased while growing on this substrate. In their
second study, they reported on a scoring system to distinguish between active and senescent UCB-MSCs
[120]. The scoring system looks at multilineage differentiations, growth rates, morphologies, passages,
immunophenotypic analysis, free radical production, and senescence-associated gene expression. Cells that
score highly on this scale are more likely to possess regenerative properties, instead of being senescent.
These studies are summarized in Table 8 and show some of the ways that stem cells can be
manipulated to optimize their therapeutic potential. While the use of viral vectors are unlikely to reach the
clinic (unless the viral component can be excised), they could still be a valuable tool for determining and
directing the differentiation of stem cells. Methods for the sorting or tracking of a speciﬁc cell population
are also important concerns when considering the use of cells.
11. TRANSPLANTATION AND MIGRATION
In the clinical setting, it is likely that stem cells will eventually be transplanted for a number of
neurodegenerative disorders, though animal studies are required to conﬁrm safety and mode of action.
This section will cover the presentations which study different aspects of this process such as the need for
immunosuppression and the targeting of the cells to the site of interest and integration.
Bjugstad and Rachubinski [122] followed up on previous studies of neonatal transplantation of
mouse NSCs into a trisomic mouse model of Down’s syndrome. Early data had suggested some beneﬁt,
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but, at 12 months, the cell survival was negligible and little behavioral improvement compared with
saline-treated animals was observed in contrast to studies when the cells were transplanted into adults.
Interestingly, the authors found that transplantation (of either saline or cells) in normal mice may have
caused some behavioral changes, suggesting that this should be carefully considered when deciding what
controls should be performed.
Continuing with neonatal transplants, Dunnett et al. [123] found that transplantation of human
progenitor cells during the ﬁrst postnatal week of mice and rats, at a point of immune system immaturity,
allowed subsequent transplantations in adulthood without the need for immunosuppression. This “neonatal
tolerization” led to the grafted cells surviving for up to 40 weeks, whereas they were fully rejected within
5 weeks if tolerization was not performed. While this observation does not really advocate performing
cell transplantations on newborns “just in case”, understanding the mechanisms behind this tolerance could
prove very important in future transplantation therapies for maximizing the effectiveness of the cells, though
paradoxically this would currently negate FDA approval for a study, as they are concerned about cell
survival and the potential for tumorgenicity or other effects.
In several studies, the beneﬁcial effects of cell transplantation do not appear to result from integration
but rather the release of growth factors. However, when integration does occur, it is unclear exactly how
this would proceed. Studying NSC transplantation into organotypic slice cultures, it has been shown that
one of the ﬁrst steps towards integration is the development of gap junctions between the transplanted
and host cells [121]. This was observed to occur before the differentiation of the transplanted cells to
electrophysiologically active neurons. Gap junction formation allows the transplanted cells to provide
survival signals and synchronization of calcium currents, protecting the host cells from death both
in culture and in murine models of purkinje cell degeneration. Prevention of gap junction formation
was found to enhance cell death and prevent the behavioral recovery previously seen following cell
transplantation.
TransplantationofhUCB-derivedneurally-inducedstemcellsintoamousemodelofglutaricaciduria
type I (an autosomal recessive human disorder that results in the accumulation of organic acids) was
shown to extend the lifespan and promote motor recovery of these mice [124]. The mode of action of this
improvement is unclear and requires further elucidation. hUCBC transplants had previously been shown to
be effective for another metabolic disorder sanﬁlippo type B, and it will be interesting to see whether their
mode of action is similar once the mechanisms for both have been determined.
Many disorders involve increased inﬂammation, and this could act as a homing signal for
transplanted cells. This was demonstrated in normal mice that had a cocktail of factors that mimic a classical
pro-inﬂammatory response injected into their hippocampus followed two days later by an intracardiac
injection of green-ﬂuorescent-protein-(GFP-) labeled monocytes. After 24hrs, cells were found within the
brain to a larger extent than in animals not given the inﬂammatory cocktail [131].
Endogenous stem cell production and migration is another important potential source of cells that
could be tapped for therapies. It is known that NSCs migrate from the subventricular zone towards the
olfactory bulb along a pathway known as the rostral migratory stream. To investigate the origin and effects
of endogenous stem cells, this pathway needs to be identiﬁed in a number of species to provide a more
detailed picture of how the pathway could change with increased species complexity. Malik et al. [117]h a v e
identiﬁed its presence within cats and dogs, thus allowing for the characterization of the rostral migratory
stream and endogenous NSCs in different species from the more traditional rodent. This could prove useful
in the development of therapies for man as well as in cats and dogs.
Treatmentsforinnereardisordersneedtobeabletoreachtheinnerearwithoutcausingdamagetothe
surrounding tissue. Syka et al. [125] demonstrated that a variety of different nanoparticles could traverse the
round window membrane to allow entry into the cochlea within 24hrs without causing any apparent damage
or hearing impairment. This suggests that these nanoparticles could be used as transporters of drugs or other
factors into the inner ear for the potential treatment of hearing or balance disorders.
These studies are summarized in Table 8.
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12. CONCLUSIONS
The 2010 ASNTR meeting provides a window into the emerging avenues of research in regenerative
medicine for the treatment of the central and peripheral nervous system.
The valuable use of models to characterize speciﬁc aspects of or provide further understanding of a
pathogenesisofadiseaseisemphasizedalongwiththepotentialuseofstemcelltransplantationasatherapy.
Speciﬁc growth factors play an important role in the etiology of many disorders and could be utilized in
treatments. One of the primary modes of action of stem cells is believed to be as a result of the secretion
of these factors to modify the microenvironment to make it more conducive to the survival of endogenous
cells (or the transplanted cells).
While it is true that the long-term contribution of these studies may prove to be minor, the path from
bench to bedside is normally a long one with considerable knowledge of the mechanisms behind the therapy
being necessary as well as the performance of extensive safety studies before the process is complete. This
means that it is currently unclear which of these studies will eventually result in a therapy. Though different
diseases frequently possess distinct anatomical and pathological characteristics, it is clear from some of
the studies reported here that overlapping themes can be observed such as the contribution of inﬂammation
or the impairment of the BBB to a number of diseases or disorders. This means that a therapy that will
inﬂuence mutual characteristics of a disease such as BBB impairment could provide some degree of beneﬁt
to multiple disorders. Therapies for different disorders are going to need to provide variable improvements
and ideally would function at any stage of a disorder. Whatever the outcome, the studies do help in piecing
together likely future therapies which in all likelihood are likely to be multifactorial, working in a number
of ways to combat or at least halt the disease process. These studies encompass methods to promote growth
factor activity which can provide support to impaired cells, possibly by altering the hostile environment by
reducing inﬂammation, as well as potentially enhancing the endogenous production of replacement cells.
Alternatively transplanted cells could also integrate, though many studies suggest that this is not the case.
Of particular note is that some of these reported studies do focus on therapies that are currently undergoing
clinical trials (e.g. NeuralStem Inc.’s neural stem cells for SCI), while others are studies that help to explain
the disease state better, a necessary step towards therapy. Many of the studies reported at the ASNTR are
expanded further in future papers as exempliﬁed by the overlap between topics at this year’s (and especially
previous) meetings compared to those published in TheScientiﬁcWorldJournal. In this way, we feel that an
overview of the topics presented at the ASNTR meeting can provide insight into the current progress of the
ﬁeld of regenerative medicine.
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